Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Rhea-AI Summary

Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York City. CEO Ian McDonald and CSO Jan Torleif Pedersen will present on Thursday, June 5, 2025, at 8:10 AM ET.

The presentation will be available via webcast on the company's investor relations website, with replay access for 60 days. Investors can schedule one-on-one meetings through Jefferies representatives.

NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and Jan Torleif Pedersen, Chief Scientific Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:

Date:	Thursday, June 5, 2025
Time:	8:10m ET
Webcast:	Click Here

To schedule a 1x1 meeting with the Company, please contact your Jefferies representative at healthcareconference@jefferies.com.

The live and archived webcast will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com

FAQ

When is Bright Minds Biosciences (DRUG) presenting at the 2025 Jefferies Healthcare Conference?

Bright Minds Biosciences will present on Thursday, June 5, 2025, at 8:10 AM ET at the Jefferies Global Healthcare Conference in New York City.

Who will be presenting for Bright Minds Biosciences (DRUG) at the Jefferies conference?

Ian McDonald, CEO, and Jan Torleif Pedersen, CSO, will present for Bright Minds Biosciences.

What therapeutic areas does Bright Minds Biosciences (DRUG) focus on?

Bright Minds Biosciences focuses on developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders.

How can investors access the Bright Minds Biosciences (DRUG) Jefferies conference presentation?

Investors can access the live and archived webcast through the company's website at brightmindsbio.com/investors under Events and Presentation. The replay will be available for 60 days.